This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.01532-07v1 52/6/2163    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kihara, R. Articles by Kohno, S. Search for Related Content PubMed PubMed Citation Articles by Kihara, R. Articles by Kohno, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2008, p. 2163-2168, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.01532-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Potency of SMP-601, a Novel Carbapenem, in Hematogenous Murine Bronchopneumonia Caused by Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus

Department of Pharmacotherapeutics, Nagasaki University Graduate School of Pharmaceutical Sciences,¹ Department of Laboratory Medicine,² Second Department of Internal Medicine, Nagasaki University Graduate School of Medical Sciences, Nagasaki, Japan³

Received 28 November 2007/ Returned for modification 23 January 2008/ Accepted 28 March 2008

We compared the potency of SMP-601, a novel carbapenem, with that of vancomycin in a murine model of hematogenous bronchopneumonia infection caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-intermediate S. aureus (VISA). The MICs of SMP-601 and vancomycin against MRSA were 2 and 1 µg/ml, respectively, while those against VISA were 2 and 8 µg/ml, respectively. Treatment with SMP-601 resulted in a significant decrease in the number of viable bacteria in the MRSA infection model (control, 100 mg/kg vancomycin, and 100 mg/kg SMP-601, 8.42 ± 0.50, 5.29 ± 0.71, and 5.50 ± 0.58 log CFU/lung, respectively,) and in the VISA infection model (control, 100 mg/kg vancomycin, and 100 mg/kg SMP-601, 9.64 ± 0.63, 8.72 ± 0.45, 7.42 ± 0.14 log CFU/lung) (mean ± standard error of the mean). The survival rate in the VISA infection model treated with SMP-601 (70%) was significantly higher than those in the other two groups (20% for vancomycin and 0% for control; P < 0.05). Histopathological examination revealed that inflammatory changes in the SMP-601-treated group were less marked than in the other two groups. The results of pharmacokinetic-pharmacodynamic analysis supported the results of the bacteriological, histopathological and survival studies. Our results demonstrate the potency of SMP-601 against MRSA and VISA in murine hematogenous pulmonary infection.

Published ahead of print on 7 April 2008.